Glück Conviction Score™ ⓘ
RPRX
Royalty Pharma plc
ⓘ
Eingeschränkte Aussagekraft — erst 61 % der Signal-Gewichte sind mit Daten unterlegt.
Effektiv: Neutral
Hoch
Bedeutung der Einstufung ⓘ
Insider
0,0
Keine Insider-Käufe
Institutionell
69,3
110 neu, 227 erhöht, 2820,5M $ netto
Aktivist
0,0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,69% (Stand: 31.05.2026)
Score-Verlauf (90 Tage)
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (12 Monate)
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 51.52 | +6.5 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 42.99 | +27.6 % vs SMA200 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 54.17 | EMA50: 51.82 | |
| MACD-Histogramm | Bärisch | 10 % | -0.157 | Bearisch | |
| RSI(14) | Neutral | 10 % | 57.3 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 45.7 | Neutral | |
| ADX(14)+DI | Bullisch | 10 % | 50.8 | +DI: 24.8 / −DI: 5.7 | |
| Z-Score(60) | Neutral | 5 % | 1.35 | In Range | |
| 52W-Position | Bullisch | 5 % | 95.3 % | Hoch 55.87 / Tief 34.56 | |
| Bollinger(20,2σ) | Neutral | 5 % | 62.4 % | Upper 56.48 / Mid 54.34 / Lower 52.19 | |
| LinReg-Slope(60) | Bullisch | 10 % | +0.1739 | R²=0.95 / annualisiert +86.5 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -64.399 | 53,98 | -3.476.116,34 | -323,1% | |
| 2026-05-20 | Urist Marshall | Officer, EVP, Research & Investments | Open Market Sale | -13.684 | 52,75 | -721.837,84 | -67,1% | |
| 2026-05-14 | Urist Marshall | Officer, EVP, Research & Investments | Open Market Sale | -13.684 | 53,06 | -726.137,35 | -67,5% | |
| 2026-05-14 | Norden Gregory | Director | Open Market Sale | -3.045 | 53,00 | -161.385,00 | -15,0% | |
| 2026-04-28 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -1.875 | 49,78 | -93.334,50 | -8,7% | |
| 2026-04-28 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -32.916 | 49,78 | -1.638.505,81 | -152,3% | |
| 2026-04-01 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -32.916 | 48,33 | -1.590.889,53 | -147,9% | |
| 2026-04-01 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -1.875 | 48,33 | -90.622,13 | -8,4% | |
| 2026-03-23 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -32.916 | 45,53 | -1.498.622,69 | -139,3% | |
| 2026-03-23 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -1.875 | 45,53 | -85.366,31 | -7,9% | |
| 2026-03-02 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -1.292 | 46,67 | -60.303,71 | -5,6% | |
| 2026-03-02 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -22.487 | 46,67 | -1.049.506,52 | -97,6% | |
| 2026-03-02 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -10.429 | 47,01 | -490.314,22 | -45,6% | |
| 2026-03-02 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -583 | 47,01 | -27.409,34 | -2,5% | |
| 2026-02-23 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -32.916 | 45,32 | -1.491.637,91 | -138,6% | |
| 2026-02-23 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -1.875 | 45,32 | -84.968,44 | -7,9% | |
| 2026-02-04 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -19.076 | 43,29 | -825.853,45 | -76,8% | |
| 2026-02-04 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -1.087 | 43,29 | -47.059,27 | -4,4% | |
| 2026-02-03 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -108.759 | 42,84 | -4.659.583,59 | -433,1% | |
| 2026-02-03 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -6.195 | 42,84 | -265.413,00 | -24,7% | |
| 2026-02-02 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -102.581 | 42,08 | -4.317.008,55 | -401,3% | |
| 2026-02-02 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -5.843 | 42,08 | -245.896,23 | -22,9% | |
| 2026-01-30 | Urist Marshall | Officer, EVP, Research & Investments | Open Market Sale | -20.000 | 41,09 | -821.810,00 | -76,4% | |
| 2026-01-23 | Urist Marshall | Officer, EVP, Research & Investments | Open Market Sale | -20.000 | 40,26 | -805.110,00 | -74,8% | |
| 2026-01-20 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -65.832 | 39,35 | -2.590.383,87 | -240,8% | |
| 2026-01-20 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -3.750 | 39,35 | -147.556,50 | -13,7% | |
| 2026-01-16 | Urist Marshall | Officer, EVP, Research & Investments | Open Market Sale | -20.000 | 39,52 | -790.346,00 | -73,5% | |
| 2026-01-09 | Urist Marshall | Officer, EVP, Research & Investments | Open Market Sale | -20.000 | 40,78 | -815.634,00 | -75,8% | |
| 2026-01-02 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -65.832 | 38,42 | -2.528.982,36 | -235,1% | |
| 2026-01-02 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -3.750 | 38,42 | -144.058,88 | -13,4% | |
| 2026-01-02 | Urist Marshall | Officer, EVP, Research & Investments | Open Market Sale | -20.000 | 38,48 | -769.650,00 | -71,5% | |
| 2025-12-26 | Urist Marshall | Officer, EVP, Research & Investments | Open Market Sale | -20.000 | 39,32 | -786.380,00 | -73,1% | |
| 2025-12-19 | Urist Marshall | Officer, EVP, Research & Investments | Open Market Sale | -20.000 | 38,38 | -767.582,00 | -71,3% | |
| 2025-12-18 | Lloyd George W. | Officer, EVP, Investments & CLO | Open Market Sale | -30.654 | 38,50 | -1.180.053,32 | -109,7% | |
| 2025-12-17 | Lloyd George W. | Officer, EVP, Investments & CLO | Open Market Sale | -79.346 | 38,57 | -3.060.280,00 | -284,4% | |
| 2025-12-16 | Urist Marshall | Officer, EVP, Research & Investments | Open Market Sale | -20.000 | 38,32 | -766.420,00 | -71,2% | |
| 2025-12-15 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -65.832 | 38,36 | -2.525.322,10 | -234,7% | |
| 2025-12-15 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -3.750 | 38,36 | -143.850,38 | -13,4% | |
| 2025-12-05 | Urist Marshall | Officer, EVP, Research & Investments | Open Market Sale | -18.242 | 39,15 | -714.223,55 | -66,4% | |
| 2025-12-05 | Urist Marshall | Officer, EVP, Research & Investments | Open Market Sale | -23.334 | 39,15 | -913.591,44 | -84,9% | |
| 2025-12-03 | Lloyd George W. | Officer, EVP, Investments & CLO | Open Market Sale | -110.000 | 39,77 | -4.375.008,00 | -406,7% | |
| 2025-12-01 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -65.832 | 39,87 | -2.624.458,51 | -243,9% | |
| 2025-12-01 | Urist Marshall | Officer, EVP, Research & Investments | Open Market Sale | -23.333 | 39,93 | -931.633,02 | -86,6% | |
| 2025-12-01 | Urist Marshall | Officer, EVP, Research & Investments | Open Market Sale | -18.242 | 39,90 | -727.855,80 | -67,7% | |
| 2025-12-01 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -3.750 | 39,87 | -149.497,50 | -13,9% | |
| 2025-11-24 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -3.126 | 38,67 | -120.882,11 | -11,2% | |
| 2025-11-24 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -55.146 | 38,67 | -2.132.291,78 | -198,2% | |
| 2025-11-24 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -10.686 | 37,96 | -405.644,83 | -37,7% | |
| 2025-11-24 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -624 | 37,96 | -23.686,73 | -2,2% | |
| 2025-11-19 | Lloyd George W. | Officer, EVP, Investments & CLO | Open Market Sale | -2.470 | 39,01 | -96.346,55 | -9,0% | |
| 2025-11-19 | Lloyd George W. | Officer, EVP, Investments & CLO | Open Market Sale | -47.798 | 38,28 | -1.829.650,08 | -170,1% | |
| 2025-11-19 | Lloyd George W. | Officer, EVP, Investments & CLO | Open Market Sale | -47.401 | 38,28 | -1.814.448,66 | -168,7% | |
| 2025-11-19 | Lloyd George W. | Officer, EVP, Investments & CLO | Open Market Sale | -25.530 | 38,28 | -977.260,32 | -90,8% | |
| 2025-11-19 | Lloyd George W. | Officer, EVP, Investments & CLO | Open Market Sale | -4.628 | 39,01 | -180.527,64 | -16,8% | |
| 2025-11-19 | Lloyd George W. | Officer, EVP, Investments & CLO | Open Market Sale | -4.599 | 39,01 | -179.393,65 | -16,7% | |
| 2025-11-19 | Lloyd George W. | Officer, EVP, Investments & CLO | Open Market Sale | -2.770 | 38,29 | -106.051,67 | -9,9% | |
| 2025-11-19 | Lloyd George W. | Officer, EVP, Investments & CLO | Open Market Sale | -230 | 39,03 | -8.977,61 | -0,8% | |
| 2025-11-17 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -3.750 | 39,30 | -147.390,00 | -13,7% | |
| 2025-11-17 | Coyne Terrance P. | Officer, EVP & CFO | Open Market Sale | -65.844 | 39,30 | -2.587.939,16 | -240,5% | |
| 2025-08-11 | Norden Gregory | Director | Open Market Sale | -33.500 | 36,23 | -1.213.748,55 | -112,8% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| MORGAN STANLEY | 43.571.633 | 55.274.069 | -11.702.436 | 2.090.131.406 | Reduziert | -21,2% | |
| Capital International Investors | 35.005.736 | 31.104.309 | 3.901.427 | 1.679.225.156 | Aufgestockt | +12,5% | |
| BlackRock, Inc. | 25.907.745 | 26.188.692 | -280.947 | 1.242.794.508 | Reduziert | -1,1% | |
| FMR LLC | 25.152.242 | 26.272.308 | -1.120.066 | 1.206.553.066 | Reduziert | -4,3% | |
| BAILLIE GIFFORD & CO | 16.155.677 | 17.008.768 | -853.091 | 774.987.825 | Reduziert | -5,0% | |
| Swedbank AB | 11.586.693 | 11.942.143 | -355.450 | 555.813.663 | Reduziert | -3,0% | |
| STATE STREET CORP | 10.989.851 | 10.649.641 | 340.210 | 527.183.152 | Aufgestockt | +3,2% | |
| Capital World Investors | 8.036.714 | 0 | 8.036.714 | 385.521.171 | Neu | +100,0% | |
| VANGUARD GROUP INC | 9.934.612 | 0 | 9.934.612 | 383.873.407 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 7.869.632 | 7.719.843 | 149.789 | 376.524.510 | Aufgestockt | +1,9% | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 7.480.633 | 11.740.594 | -4.259.961 | 358.845.965 | Reduziert | -36,3% | |
| Caledonia (Private) Investments Pty Ltd | 7.168.399 | 7.377.038 | -208.639 | 343.868.100 | Reduziert | -2,8% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.531.886 | 0 | 4.531.886 | 217.394.571 | Neu | +100,0% | |
| VICTORY CAPITAL MANAGEMENT INC | 3.853.808 | 5.106.905 | -1.253.097 | 184.867.170 | Reduziert | -24,5% | |
| NORTHERN TRUST CORP | 3.808.735 | 4.003.322 | -194.587 | 182.705.016 | Reduziert | -4,9% | |
| ROYAL LONDON ASSET MANAGEMENT LTD | 3.808.353 | 179.683 | 3.628.670 | 182.686.693 | Aufgestockt | +2019,5% | |
| Invesco Ltd. | 3.752.399 | 1.502.171 | 2.250.228 | 180.002.595 | Aufgestockt | +149,8% | |
| AQR CAPITAL MANAGEMENT LLC | 3.782.038 | 2.563.654 | 1.218.384 | 179.646.825 | Aufgestockt | +47,5% | |
| Patient Capital Management, LLC | 3.643.716 | 3.333.675 | 310.041 | 174.789.053 | Aufgestockt | +9,3% | |
| BANK OF AMERICA CORP /DE/ | 3.495.846 | 2.708.925 | 786.921 | 167.695.755 | Aufgestockt | +29,0% | |
| Legal & General Group Plc | 3.362.872 | 3.088.098 | 274.774 | 161.316.967 | Aufgestockt | +8,9% | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 3.095.766 | 3.118.865 | -23.099 | 148.503.894 | Reduziert | -0,7% | |
| Amundi | 3.088.773 | 2.679.379 | 409.394 | 148.168.441 | Aufgestockt | +15,3% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 3.027.899 | 2.913.398 | 114.501 | 145.248.315 | Aufgestockt | +3,9% | |
| CITADEL ADVISORS LLC | 2.939.469 | 5.360.665 | -2.421.196 | 141.006.328 | Reduziert | -45,2% | |
| JANE STREET GROUP, LLC | 2.772.482 | 5.042.709 | -2.270.227 | 132.995.961 | Reduziert | -45,0% | |
| NORGES BANK | 3.414.165 | 0 | 3.414.165 | 131.923.336 | Neu | +100,0% | |
| NEW SOUTH CAPITAL MANAGEMENT INC | 2.625.863 | 2.928.778 | -302.915 | 125.962.648 | Reduziert | -10,3% | |
| Regal Partners Ltd | 2.624.472 | 2.640.708 | -16.236 | 125.895.921 | Reduziert | -0,6% | |
| GOLDMAN SACHS GROUP INC | 2.547.546 | 1.575.900 | 971.646 | 122.205.784 | Aufgestockt | +61,7% | |
| DEUTSCHE BANK AG\ | 2.453.303 | 2.185.079 | 268.224 | 117.684.945 | Aufgestockt | +12,3% | |
| Dorsey Asset Management, LLC | 2.276.570 | 2.259.469 | 17.101 | 109.207.063 | Aufgestockt | +0,8% | |
| TWO SIGMA INVESTMENTS, LP | 2.251.525 | 681.248 | 1.570.277 | 108.005.654 | Aufgestockt | +230,5% | |
| MARSHALL WACE, LLP | 2.120.692 | 396.738 | 1.723.954 | 101.729.595 | Aufgestockt | +434,5% | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 2.010.398 | 3.313.265 | -1.302.867 | 96.438.792 | Reduziert | -39,3% | |
| UBS Group AG | 1.812.203 | 2.005.831 | -193.628 | 86.931.378 | Reduziert | -9,7% | |
| FRANKLIN RESOURCES INC | 1.718.182 | 677.484 | 1.040.698 | 82.421.191 | Aufgestockt | +153,6% | |
| HOMESTEAD ADVISERS CORP | 1.653.042 | 1.671.542 | -18.500 | 78.908.894 | Reduziert | -1,1% | |
| Clark Capital Management Group, Inc. | 1.639.968 | 1.753.810 | -113.842 | 78.669.278 | Reduziert | -6,5% | |
| HSBC HOLDINGS PLC | 1.544.018 | 57.998 | 1.486.020 | 74.000.087 | Aufgestockt | +2562,2% | |
| Qube Research & Technologies Ltd | 1.524.511 | 2.469.181 | -944.670 | 73.130.793 | Reduziert | -38,3% | |
| RAYMOND JAMES FINANCIAL INC | 1.524.018 | 1.467.599 | 56.419 | 72.686.508 | Aufgestockt | +3,8% | |
| Mitsubishi UFJ Trust & Banking Corp | 1.494.475 | 1.764.269 | -269.794 | 71.689.966 | Reduziert | -15,3% | |
| Russell Investments Group, Ltd. | 1.397.958 | 1.398.972 | -1.014 | 66.809.416 | Reduziert | -0,1% | |
| Squarepoint Ops LLC | 1.349.516 | 1.556.241 | -206.725 | 64.736.283 | Reduziert | -13,3% | |
| EVENTIDE ASSET MANAGEMENT, LLC | 1.312.534 | 1.296.826 | 15.708 | 62.604.127 | Aufgestockt | +1,2% | |
| Sumitomo Mitsui Trust Group, Inc. | 1.273.705 | 1.268.044 | 5.661 | 61.099.629 | Aufgestockt | +0,4% | |
| Brandywine Global Investment Management, LLC | 1.579.252 | 0 | 1.579.252 | 61.022.297 | Neu | +100,0% | |
| JPMORGAN CHASE & CO | 1.518.610 | 0 | 1.518.610 | 58.679.167 | Neu | +100,0% | |
| Swiss National Bank | 1.191.100 | 1.125.400 | 65.700 | 57.137.067 | Aufgestockt | +5,8% |
Top-Fondshalter (Stand: 31.03.2026) ⓘ
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) |
|---|---|---|---|---|---|
| MORGAN STANLEY | 43.571.633 | 55.274.069 | -21,2% | 2.090.131.406 | 12,79 |
| Capital International Investors | 35.005.736 | 31.104.309 | +12,5% | 1.679.225.156 | 10,27 |
| BlackRock, Inc. | 25.907.745 | 26.188.692 | -1,1% | 1.242.794.508 | 7,60 |
| FMR LLC | 25.152.242 | 26.272.308 | -4,3% | 1.206.553.066 | 7,38 |
| BAILLIE GIFFORD & CO | 16.155.677 | 17.008.768 | -5,0% | 774.987.825 | 4,74 |
| Swedbank AB | 11.586.693 | 11.942.143 | -3,0% | 555.813.663 | 3,40 |
| STATE STREET CORP | 10.989.851 | 10.649.641 | +3,2% | 527.183.152 | 3,22 |
| Capital World Investors | 8.036.714 | 0 | +100,0% | 385.521.171 | 2,36 |
| GEODE CAPITAL MANAGEMENT, LLC | 7.869.632 | 7.719.843 | +1,9% | 376.524.510 | 2,30 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 7.480.633 | 11.740.594 | -36,3% | 358.845.965 | 2,20 |
| Caledonia (Private) Investments Pty Ltd | 7.168.399 | 7.377.038 | -2,8% | 343.868.100 | 2,10 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.531.886 | 0 | +100,0% | 217.394.571 | 1,33 |
| VICTORY CAPITAL MANAGEMENT INC | 3.853.808 | 5.106.905 | -24,5% | 184.867.170 | 1,13 |
| NORTHERN TRUST CORP | 3.808.735 | 4.003.322 | -4,9% | 182.705.016 | 1,12 |
| ROYAL LONDON ASSET MANAGEMENT LTD | 3.808.353 | 179.683 | +2019,5% | 182.686.693 | 1,12 |
| Invesco Ltd. | 3.752.399 | 1.502.171 | +149,8% | 180.002.595 | 1,10 |
| AQR CAPITAL MANAGEMENT LLC | 3.782.038 | 2.563.654 | +47,5% | 179.646.825 | 1,10 |
| Patient Capital Management, LLC | 3.643.716 | 3.333.675 | +9,3% | 174.789.053 | 1,07 |
| BANK OF AMERICA CORP /DE/ | 3.495.846 | 2.708.925 | +29,0% | 167.695.755 | 1,03 |
| Legal & General Group Plc | 3.362.872 | 3.088.098 | +8,9% | 161.316.967 | 0,99 |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 31.03.2026 | ✓ | 579 | 361,1 | 16.841 |
| 31.12.2025 | ✓ | 526 | 426,9 | 16.226 |
| 30.09.2025 | ✓ | 489 | 380,2 | 13.160 |
| 30.06.2025 | ✓ | 454 | 346,1 | 12.228 |
| 31.03.2025 | ✓ | 442 | 332,4 | 10.135 |
| 31.12.2024 | ✓ | 405 | 368,6 | 9.281 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) ⓘ |
|---|---|---|
| NORGES BANK | 3.414.165 | 131.923.336 |
| PFA Pension, Forsikringsaktieselskab | 1.118.023 | 43.591.729 |
| TUDOR INVESTMENT CORP ET AL | 924.819 | 35.735.006 |
| Davern Capital Partners, LP | 840.650 | 32.482.716 |
| Burkehill Global Management, LP | 500.000 | 19.320.000 |
| Jain Global LLC | 365.430 | 14.120.215 |
| Taproot Management LP | 284.687 | 11.000.306 |
| United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund | 234.551 | 9.063.051 |
| Foster Victor Wealth Advisors, LLC | 180.657 | 7.144.984 |
| FIDEURAM - INTESA SANPAOLO PRIVATE BANKING S.P.A. | 127.419 | 4.923.468 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| MORGAN STANLEY | 55.274.069 | 11.110.115 | +25.2 % | 2.135.790.095 |
| CITADEL ADVISORS LLC | 5.360.665 | 4.781.792 | +826.1 % | 207.136.096 |
| Capital International Investors | 31.104.309 | 3.891.615 | +14.3 % | 1.201.870.500 |
| JANE STREET GROUP, LLC | 5.042.709 | 1.716.849 | +51.6 % | 194.850.276 |
| Regal Partners Ltd | 2.640.708 | 1.205.582 | +84.0 % | 102.036.956 |
| Squarepoint Ops LLC | 1.556.241 | 870.454 | +126.9 % | 60.133.152 |
| D. E. Shaw & Co., Inc. | 838.613 | 698.585 | +498.9 % | 32.404.007 |
| CAISSE DE DEPOT ET PLACEMENT DU QUEBEC | 911.685 | 643.985 | +240.6 % | 35.227.508 |
| Amundi | 2.679.379 | 609.394 | +29.4 % | 103.531.205 |
| AQR CAPITAL MANAGEMENT LLC | 2.563.654 | 602.568 | +30.7 % | 99.059.574 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | 116.839 | -2.118.294 | -94.8 % | 4.514.659 |
| FMR LLC | 26.272.308 | -1.714.406 | -6.1 % | 1.015.161.996 |
| MARSHALL WACE, LLP | 396.738 | -1.086.938 | -73.3 % | 15.329.957 |
| VANGUARD GROUP INC | 9.934.612 | -1.001.926 | -9.2 % | 383.873.407 |
| HRT FINANCIAL LP | 76.741 | -867.910 | -91.9 % | 2.965 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 160.391 | -533.030 | -76.9 % | 6.197.508 |
| TWO SIGMA INVESTMENTS, LP | 681.248 | -503.063 | -42.5 % | 26.323.423 |
| BAILLIE GIFFORD & CO | 17.008.768 | -363.734 | -2.1 % | 657.218.795 |
| Parallax Volatility Advisers, L.P. | 9.509 | -360.691 | -97.4 % | 367.428 |
| Robeco Institutional Asset Management B.V. | 949.472 | -299.147 | -24.0 % | 36.687.601 |
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck |
|---|---|---|---|---|---|---|
| 14.05.2026 | Capital International Investors | Passiv (13G/A) | 8,80 % | 37.772.419 | +1,10 pp | |
| 20.02.2026 | Severgnini Achille G. | Aktivist (13D/A) | 5,70 % | 24.223.082 | -1,20 pp | |
| 20.02.2026 | R & H Trust Co. (Guernsey) Limited | Aktivist (13D/A) | 5,70 % | 24.223.082 | -1,20 pp | |
| 13.02.2026 | Capital International Investors | Passiv (13G/A) | 7,70 % | 32.745.526 | +1,10 pp | |
| 13.11.2025 | Capital International Investors | Passiv (13G/A) | 6,60 % | 28.512.128 | +1,10 pp | |
| 05.11.2025 | Abigail P. Johnson | Passiv (13G/A) | 6,50 % | 27.900.714 | -2,60 pp | |
| 05.11.2025 | FMR LLC | Passiv (13G/A) | 6,50 % | 27.900.714 | -2,60 pp | |
| 30.10.2025 | The Vanguard Group | Passiv (13G/A) | 2,52 % | 10.936.538 | -6,02 pp | |
| 14.08.2025 | GAP Coinvestments CDA, L.P. | Passiv (13G/A) | 3,20 % | 14.243.870 | -2,40 pp | |
| 14.08.2025 | General Atlantic GenPar (Lux) SCSp | Passiv (13G/A) | Ausstieg | 0 | -0,30 pp | |
| 14.08.2025 | GAP Coinvestments IV, LLC | Passiv (13G/A) | 3,20 % | 14.243.870 | -2,40 pp | |
| 14.08.2025 | GA RP Holding, Ltd. | Passiv (13G/A) | Ausstieg | 0 | -0,30 pp | |
| 14.08.2025 | GA RP Holding, L.P. | Passiv (13G/A) | Ausstieg | 0 | -0,30 pp | |
| 14.08.2025 | GAP Coinvestments III, LLC | Passiv (13G/A) | 3,20 % | 14.243.870 | -2,40 pp | |
| 14.08.2025 | General Atlantic GenPar (Bermuda), L.P. | Passiv (13G/A) | Ausstieg | 0 | -0,30 pp | |
| 14.08.2025 | GAP Coinvestments V, LLC | Passiv (13G/A) | 3,20 % | 14.243.870 | -2,40 pp | |
| 14.08.2025 | General Atlantic, L.P. | Passiv (13G/A) | 3,20 % | 14.243.870 | -2,40 pp | |
| 14.08.2025 | General Atlantic (SPV) GP, LLC | Passiv (13G/A) | 3,20 % | 14.243.870 | -2,00 pp | |
| 14.08.2025 | General Atlantic Partners (Lux) SCSp | Passiv (13G/A) | Ausstieg | 0 | -0,30 pp | |
| 14.08.2025 | General Atlantic Partners (Bermuda) EU, L.P. | Passiv (13G/A) | Ausstieg | 0 | -0,30 pp | |
| 14.08.2025 | General Atlantic Partners AIV-1 B, L.P. | Passiv (13G/A) | 3,20 % | 14.243.870 | -2,00 pp | |
| 14.08.2025 | General Atlantic (Lux) S.a r.l. | Passiv (13G/A) | Ausstieg | 0 | Neu | |
| 14.08.2025 | General Atlantic (RP) Collections, LLC | Passiv (13G/A) | 3,20 % | 14.243.870 | -2,00 pp | |
| 14.08.2025 | General Atlantic GenPar, L.P. | Passiv (13G/A) | 3,20 % | 14.243.870 | -2,00 pp | |
| 14.08.2025 | General Atlantic Partners (Bermuda) IV, L.P. | Passiv (13G/A) | Ausstieg | 0 | -0,30 pp | |
| 14.08.2025 | General Atlantic Partners AIV-1 A, L.P. | Passiv (13G/A) | 3,20 % | 14.243.870 | -2,00 pp | |
| 14.08.2025 | GAP (Bermuda) L.P. | Passiv (13G/A) | Ausstieg | 0 | -0,30 pp | |
| 13.08.2025 | Capital International Investors | Passiv (13G) | 5,50 % | 23.111.998 | Neu | |
| 05.08.2025 | Morgan Stanley Investment Management Inc. | Passiv (13G/A) | 8,50 % | 35.864.664 | +0,90 pp | |
| 05.08.2025 | Morgan Stanley | Passiv (13G/A) | 9,20 % | 38.907.011 | +1,00 pp | |
| 23.05.2025 | Legorreta G. Pablo | Aktivist (13D) | 19,74 % | 103.112.796 | Neu | The information in Items 3, 5 and 6 of this Schedule 13D is incorporated herein by refer… |
| 23.05.2025 | Legorreta Investments, LLC | Aktivist (13D) | 8,14 % | 37.535.019 | Neu | The information in Items 3, 5 and 6 of this Schedule 13D is incorporated herein by refer… |
| 12.05.2025 | FMR LLC | Passiv (13G/A) | 9,10 % | 39.245.593 | +3,20 pp | |
| 12.05.2025 | Abigail P. Johnson | Passiv (13G/A) | 9,10 % | 39.245.593 | +3,20 pp | |
| 02.05.2025 | R & H Trust Co. (Guernsey) Limited | Aktivist (13D/A) | 6,90 % | 29.926.170 | -1,40 pp | |
| 02.05.2025 | Severgnini Achille G. | Aktivist (13D/A) | 6,90 % | 29.926.170 | -1,40 pp | |
| 21.02.2025 | R & H Trust Co. (Guernsey) Limited | Aktivist (13D/A) | 8,30 % | 36.001.535 | -0,90 pp | |
| 21.02.2025 | Severgnini Achille G. | Aktivist (13D/A) | 8,30 % | 36.001.535 | Neu | |
| 12.02.2025 | FMR LLC | Passiv (13G/A) | 5,90 % | 26.309.327 | Neu | |
| 12.02.2025 | Abigail P. Johnson | Passiv (13G/A) | 5,90 % | 26.309.327 | Neu |
Stammdaten
Royalty Pharma plc ist ein Käufer von biopharmazeutischen Lizenzgebühren und Förderer von Innovationen in der biopharmazeutischen Industrie in den Vereinigten Staaten. Das Unternehmen ist auch in der Identifizierung, Bewertung und dem Erwerb von Lizenzgebühren auf verschiedene biopharmazeutische Therapien tätig. Darüber hinaus arbeitet das Unternehmen mit Innovatoren aus akademischen Institutionen, Forschungskrankenhäusern und gemeinnützigen Organisationen, kleinen und mittelständischen Biotechnologieunternehmen und Pharmaunternehmen zusammen. Sein Portfolio besteht aus Lizenzgebühren auf ungefähr 35 vermarktete Therapien und 10 Produktkandidaten im Entwicklungsstadium, die verschiedene therapeutische Bereiche wie Seltene Krankheiten, Krebs, Neurologie, Infektionskrankheiten, Hämatologie und Diabetes abdecken. Das Unternehmen wurde 1996 gegründet und hat seinen Sitz in New York, New York.
Unternehmen & Branche
| Name | Royalty Pharma plc |
|---|---|
| Ticker | RPRX |
| CIK | 0001802768 |
| Boerse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | G7709Q104 |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 31,21 Mrd. USD |
| KGV (P/E) | 31,06 |
| Beta | 0,41 |
| Dividendenrendite | 0,02 % |
Bewertung
| KUV (P/S) | 13,12 vs. 7,22 (2021) ▲ |
|---|---|
| EV/EBITDA | 25,3 vs. 15,2 (2021) ▲ |
| FCF-Rendite | 8,0 % vs. 12,2 % (2021) ▼ |
| Buyback-Rendite | 3,9 % vs. 0,0 % (2021) ▲ |
Qualität & Bilanz
| Operative Marge | 65,6 % vs. 62,5 % (2021) ▲ |
|---|---|
| Nettomarge | 32,4 % vs. 27,1 % (2021) ▲ |
| ROIC | 8,6 % vs. 8,7 % (2021) ▼ |
| Nettoverschuldung/EBITDA | 5,3 vs. 3,8 (2021) ▲ |
| Zinsdeckungsgrad | 5,1 vs. 8,6 (2021) ▼ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | Verlauf |
|---|---|---|---|---|---|---|
| Bewertung | ||||||
| KUV (P/S) | 7,22 | 7,74 | 7,19 | 6,70 | 9,17 | |
| EV/EBITDA | 15,2 | 72,6 | 15,1 | 16,9 | 19,3 | |
| FCF-Rendite | 12,2 % | 12,4 % | 17,6 % | 18,3 % | 11,4 % | |
| Buyback-Rendite | 0,0 % | 0,0 % | 1,8 % | 1,5 % | 5,6 % | |
| Qualität & Bilanz | ||||||
| Operative Marge | 62,5 % | 13,7 % | 63,4 % | 57,1 % | 65,6 % | |
| Nettomarge | 27,1 % | 1,9 % | 48,2 % | 37,9 % | 32,4 % | |
| ROIC | 8,7 % | 0,6 % | 18,5 % | 11,3 % | 8,6 % | |
| Nettoverschuldung/EBITDA | 3,8 | 17,3 | 3,8 | 5,2 | 5,3 | |
| Zinsdeckungsgrad | 8,6 | 1,6 | 8,0 | 5,7 | 5,1 | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance »
Finanzkennzahlen (SEC XBRL) ⓘ
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | 630.576.000 | 294.690.000 | 0,67 | 19.815.415.000 | |
| 2025-12-31 | 10-K | 2.378.193.000 | 770.947.000 | 1,78 | 19.620.780.000 | |
| 2025-09-30 | 10-Q | 609.291.000 | 288.217.000 | 0,67 | 19.347.280.000 | |
| 2025-06-30 | 10-Q | 578.665.000 | 30.176.000 | 0,07 | 18.323.000.000 | |
| 2025-03-31 | 10-Q | 568.247.000 | 238.349.000 | 0,55 | 17.608.256.000 | |
| 2024-12-31 | 10-K | 2.263.576.000 | 858.983.000 | 1,91 | 18.222.715.000 | |
| 2024-09-30 | 10-Q | 564.690.000 | 543.987.000 | 1,21 | 18.042.242.000 | |
| 2024-06-30 | 10-Q | 537.267.000 | 102.004.000 | 0,23 | 17.656.579.000 | |
| 2024-03-31 | 10-Q | 567.978.000 | 4.778.000 | 0,01 | 16.130.886.000 | |
| 2023-12-31 | 10-K | 2.354.554.000 | 1.134.834.000 | 2,53 | 16.381.851.000 | |
| 2023-09-30 | 10-Q | 536.313.000 | 72.114.000 | 0,16 | 15.855.524.000 | |
| 2023-06-30 | 10-Q | 538.202.000 | 227.625.000 | 0,50 | 17.121.482.000 | |
| 2023-03-31 | 10-Q | 683.971.000 | 340.755.000 | 0,76 | 17.074.121.000 | |
| 2022-12-31 | 10-K | 2.237.215.000 | 42.832.000 | 0,10 | 16.813.466.000 | |
| 2022-09-30 | 10-Q | 573.463.000 | 142.651.000 | 0,32 | 17.672.605.000 | |
| 2022-06-30 | 10-Q | 535.955.000 | 304.504.000 | 0,70 | 17.740.413.000 | |
| 2022-03-31 | 10-Q | 562.049.000 | 51.761.000 | 0,12 | 17.378.888.000 | |
| 2021-12-31 | 10-K | 2.289.463.000 | 619.728.000 | 1,49 | 17.515.865.000 | |
| 2021-09-30 | 10-Q | 585.773.000 | 101.929.000 | 0,24 | 17.732.358.000 | |
| 2021-06-30 | 10-Q | 554.963.000 | 440.776.000 | 1,08 | 16.514.913.000 |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| Financial Royalty Assets | 2,3 Mrd. | 2,1 Mrd. | 2,2 Mrd. | 2,1 Mrd. | 2,1 Mrd. | 95,1 % | +5,2% | |
| Royalty Income Other | 117,0 Mio. | 114,2 Mio. | 156,8 Mio. | 112,1 Mio. | 53,1 Mio. | 4,9 % | +2,5% | |
| Intangible Royalty Assets | – | – | – | – | 171,2 Mio. | – | – |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 06.05.2026 | 630,6 Mio. USD | 0,67 |
| Q3 2025 | 30.09.2025 | 05.11.2025 | 609,3 Mio. USD | 0,67 |
| Q2 2025 | 30.06.2025 | 05.11.2025 | 578,7 Mio. USD | 0,07 |
| Q1 2025 | 31.03.2025 | 06.05.2026 | 568,2 Mio. USD | 0,55 |
| Q3 2024 | 30.09.2024 | 05.11.2025 | 564,7 Mio. USD | 1,21 |
| Q2 2024 | 30.06.2024 | 06.08.2025 | 537,3 Mio. USD | 0,23 |
| Q1 2024 | 31.03.2024 | 08.05.2025 | 568,0 Mio. USD | 0,01 |
| Q3 2023 | 30.09.2023 | 06.11.2024 | 536,3 Mio. USD | 0,16 |
| Q2 2023 | 30.06.2023 | 08.08.2024 | 538,2 Mio. USD | 0,50 |
Einreichungs-Historie (10-K / 10-Q)
SEC-Einreichungs-Historie der Quartalsberichte (10-Q) und Jahresberichte
(10-K) der letzten sechs Jahre. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 06.05.2026 | 10-Q | 31.03.2026 | 36 Tage | SEC » |
| 11.02.2026 | 10-K | 31.12.2025 | 42 Tage | SEC » |
| 05.11.2025 | 10-Q | 30.09.2025 | 36 Tage | SEC » |
| 06.08.2025 | 10-Q | 30.06.2025 | 37 Tage | SEC » |
| 08.05.2025 | 10-Q | 31.03.2025 | 38 Tage | SEC » |
| 12.02.2025 | 10-K | 31.12.2024 | 43 Tage | SEC » |
| 06.11.2024 | 10-Q | 30.09.2024 | 37 Tage | SEC » |
| 08.08.2024 | 10-Q | 30.06.2024 | 39 Tage | SEC » |
| 09.05.2024 | 10-Q | 31.03.2024 | 39 Tage | SEC » |
| 15.02.2024 | 10-K | 31.12.2023 | 46 Tage | SEC » |
| 08.11.2023 | 10-Q | 30.09.2023 | 39 Tage | SEC » |
| 08.08.2023 | 10-Q | 30.06.2023 | 39 Tage | SEC » |
| 09.05.2023 | 10-Q | 31.03.2023 | 39 Tage | SEC » |
| 15.02.2023 | 10-K | 31.12.2022 | 46 Tage | SEC » |
| 08.11.2022 | 10-Q | 30.09.2022 | 39 Tage | SEC » |
| 04.08.2022 | 10-Q | 30.06.2022 | 35 Tage | SEC » |
| 05.05.2022 | 10-Q | 31.03.2022 | 35 Tage | SEC » |
| 15.02.2022 | 10-K | 31.12.2021 | 46 Tage | SEC » |
| 10.11.2021 | 10-Q | 30.09.2021 | 41 Tage | SEC » |
| 11.08.2021 | 10-Q | 30.06.2021 | 42 Tage | SEC » |
| 11.05.2021 | 10-Q | 31.03.2021 | 41 Tage | SEC » |
| 24.02.2021 | 10-K | 31.12.2020 | 55 Tage | SEC » |
| 12.11.2020 | 10-Q | 30.09.2020 | 43 Tage | SEC » |
| 12.08.2020 | 10-Q | 30.06.2020 | 43 Tage | SEC » |
Filing-Analyse (10-K / 10-Q)
Narrative-Analyse der letzten Quartals-/Jahresberichte durch Claude (nur Coverage-Gruppen-Mitglieder). Keine Anlageberatung — der qualitative Score dient der Einordnung, nicht als Kaufempfehlung; siehe allgemeiner Hinweis am Seitenende.
| Datum | Form | Stimmung | Guidance | Qualitativ | Zusammenfassung | |
|---|---|---|---|---|---|---|
| 11.02.2026 | 10-K | 0,18 | ? | 62,0 | Royalty Pharma erzielte 2025 starkes operatives Wachstum mit Portfolio-Einnahmen von 3,25 Mrd. USD (+16 %) und Adjusted EBITDA von 2,97 Mrd.… | |
|
Zusammenfassung: Royalty Pharma erzielte 2025 starkes operatives Wachstum mit Portfolio-Einnahmen von 3,25 Mrd. USD (+16 %) und Adjusted EBITDA von 2,97 Mrd. USD (+15,6 %), gestützt durch die im Mai 2025 abgeschlossene Internalisierung des Managements. Die Gesamtverschuldung stieg jedoch erheblich auf 9,18 Mrd. USD an, während der Kassenbestand von 929 Mio. auf 619 Mio. USD sank; umfangreiche Aktienrückkäufe von 1,2 Mrd. USD belasteten die Liquidität zusätzlich. Ein ungelöster Royalty-Streit mit Vertex über die deuterierte Ivacaftor-Komponente von Alyftrek sowie die ausgeprägte Portfoliokonzentration (Top-5-Produkte = 61 % der Einnahmen) bleiben wesentliche Risiken. Die Term-Loan-Fälligkeit von 380 Mio. USD im Juli 2026 ist kurzfristig zu beobachten, erscheint bei vorhandenen Kreditlinien jedoch handhabbar. Guidance-Zitate:
Red Flags:
|
||||||
Kritische 8-K Meldungen ⓘ
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 03.08.2020 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 03.08.2020 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-04-22 | 3 | 49,48 | 148 |
| 2026-04-17 | 3.415 | 48,48 | 165.559 |
| 2026-04-16 | 728 | 48,70 | 35.454 |
| 2026-04-08 | 3 | 46,87 | 141 |
| 2026-03-09 | 124 | 45,41 | 5.631 |
| 2026-02-27 | 1.232 | 45,36 | 55.884 |
| 2026-02-25 | 185.721 | 45,40 | 8.431.733 |
| 2026-02-20 | 8 | 45,11 | 361 |
| 2026-02-03 | 290 | 42,36 | 12.284 |
| 2026-01-26 | 21 | 40,40 | 848 |
| 2025-12-26 | 58.764 | 39,25 | 2.306.487 |